Cyclic GMP and Nitric Oxide Synthase in Aging and Alzheimer's Disease

被引:103
作者
Domek-Lopacinska, Katarzyna Urszula [1 ]
Strosznajder, Joanna B. [1 ]
机构
[1] Polish Acad Sci, Dept Cellular Signaling, M Mossakowski Med Res Ctr, PL-02106 Warsaw, Poland
关键词
Aging; Alzheimer's disease; Brain; Cyclic GMP; Memory; Nitric oxide; Phosphodiesterases; AGE-RELATED-CHANGES; SOLUBLE GUANYLYL CYCLASE; AMYLOID-BETA PEPTIDE; RAT-BRAIN; DEPENDENT EXPRESSION; OXIDATIVE STRESS; MICE DEFICIENT; OBJECT MEMORY; MOUSE MODEL; PC12; CELLS;
D O I
10.1007/s12035-010-8104-x
中图分类号
Q189 [神经科学];
学科分类号
071006 ;
摘要
Cyclic guanosine monophosphate (cGMP) is an important secondary messenger synthesized by the guanylyl cyclases which are found in the soluble (sGC) and particular isoforms. In the central nervous system, the nitric oxide (NO)-sensitive sGC isoform is the major enzyme responsible for cGMP synthesis. Phosphodiesterases (PDEs) are enzymes for hydrolysis of cGMP in the brain, and they are mainly isoforms 2, 5, and 9. The NO/cGMP signaling pathway has been shown to play an important role in the process underlying learning and memory. Aging is associated with an increase in PDE expression and activity and a decrease in cGMP concentration. In addition, aging is also associated with an enhancement of neuronal NO synthase, a lowering of endothelial, and no alteration in inducible activity. The observed changes in NMDA receptor density along with the Ca(2+)/NO/cGMP pathway underscore the lower synaptic plasticity and cognitive performance during aging. This notion is in agreement with last data indicating that inhibitors of PDE2 and PDE9 improve learning and memory in older rats. In this review, we focus on recent studies supporting the role of Ca(2+)/NO/cGMP pathway in aging and Alzheimer's disease.
引用
收藏
页码:129 / 137
页数:9
相关论文
共 60 条
[1]   Reduction in asymmetrical dimethylarginine, an endogenous nitric oxide synthase inhibitor, in the cerebrospinal fluid during aging and in patients with Alzheimer's disease [J].
Abe, T ;
Tohgi, H ;
Murata, T ;
Isobe, C ;
Sato, C .
NEUROSCIENCE LETTERS, 2001, 312 (03) :177-179
[2]  
ATOCHIN DN, 2007, J CLIN INVEST, V117, P961
[3]   Reduced expression of NO-sensitive guanylyl cyclase in reactive astrocytes of Alzheimer disease, Creutzfeldt-Jakob disease, and multiple sclerosis brains [J].
Baltrons, MA ;
Pifarré, P ;
Ferrer, I ;
Carot, JM ;
García, A .
NEUROBIOLOGY OF DISEASE, 2004, 17 (03) :462-472
[4]  
BARGER SW, 1995, J NEUROCHEM, V64, P2087
[5]   Cyclic nucleotide phosphodiesterases: Molecular regulation to clinical use [J].
Bender, Andrew T. ;
Beavo, Joseph A. .
PHARMACOLOGICAL REVIEWS, 2006, 58 (03) :488-520
[6]   Nitric oxide has dual opposite roles during early and late phases of apoptosis in cerebellar granule neurons [J].
Bobba, Antonella ;
Atlante, Anna ;
Moro, Loredana ;
Calissano, Pietro ;
Marra, Ersilia .
APOPTOSIS, 2007, 12 (09) :1597-1610
[7]   REDUCED NITRIC-OXIDE RESPONSIVE SOLUBLE GUANYLYL CYCLASE ACTIVITY IN THE SUPERIOR TEMPORAL CORTEX OF PATIENTS WITH ALZHEIMERS-DISEASE [J].
BONKALE, WL ;
WINBLAD, B ;
RAVID, R ;
COWBURN, RF .
NEUROSCIENCE LETTERS, 1995, 187 (01) :5-8
[8]   Phosphodiesterase-5 inhibition abolishes neuron apoptosis induced by chronic hypoxia independently of hypoxia-inducible factor-1α signaling [J].
Caretti, Anna ;
Bianciardi, Paola ;
Ronchi, Raffaella ;
Fantacci, Monica ;
Guazzi, Marco ;
Samaja, Michele .
EXPERIMENTAL BIOLOGY AND MEDICINE, 2008, 233 (10) :1222-1230
[9]   Aging modulates nitric oxide synthesis and cGMP levels in hippocampus and cerebellum -: Effects of amyloid β peptide [J].
Chalimoniuk, M ;
Strosznajder, JB .
MOLECULAR AND CHEMICAL NEUROPATHOLOGY, 1998, 35 (1-3) :77-95
[10]   Amyloid beta enhances cytosolic phospholipase A2 level and arachidonic acid release via nitric oxide in APP-transfected PC12 cells [J].
Chalimoniuk, Malgorzata ;
Stolecka, Anna ;
Cakala, Magdalena ;
Hauptmann, Susane ;
Schulz, Kris ;
Lipka, Uta ;
Leuner, Kristine ;
Eckert, Anne ;
Muller, Walter E. ;
Strosznajder, Joanna B. .
ACTA BIOCHIMICA POLONICA, 2007, 54 (03) :611-623